Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
New Mexico Cancer Research Alliance
Study ID
NCT01607554
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Irinotecan — DRUG
    180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician

Study Details

Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotecan. This factor is elevated in roughly 30% of NSCLC cases. Irinotecan is an agent that inhibits the enzyme called topoisomerase I that is involved in cell growth, and it has been FDA approved for 17 years for another type of cancer.

Key Dates

Start date
Apr 30, 2012
Status verified
Mar 2018
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan
    The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.

Primary Outcome Measure

Tumor Response [ Time Frame: 8 weeks ]

Locations (3)

FacilityCityStateZIPSite coordinators
Hematology Oncology AssociatesAlbuquerqueNew Mexico87106-
University of New Mexico Cancer CenterAlbuquerqueNew Mexico87131-
New Mexico Cancer Care AssociatesSanta FeNew Mexico87505-

Find similar trials in Albuquerque, NM

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Hematology Oncology Associates· Albuquerque, NMUniversity of New Mexico Cancer Center· Albuquerque, NMNew Mexico Cancer Care Associates· Santa Fe, NM

Related Studies